New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography

May 18, 2022
Category: Press Releases

Research presented at the 2022 SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances radiologists’ screening performance


NASHUA, N.H., May 18, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis (DBT) will be presented at the Society of Breast Imaging (SBI/ACR) Breast Imaging Symposium, taking place May 16-19 in Sava... Continue reading

Tags: Press Releases

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

May 17, 2022
Category: iNFORMED - Blog

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

   

iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT) – the world’s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation based on age, breast density and mammographic fea... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Density Breast Tomosynthesis Density Assessment Software Technology
2022-05-17-ProFound-AI-Risk-Blog.jpg

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

May 16, 2022
Category: Press Releases

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

  

NASHUA, N.H., May 16, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that promising clinical research supporting ProFou... Continue reading

Tags: Press Releases

iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference on May 17th, 2022

May 12, 2022
Category: Press Releases

NASHUA, N.H., May 12, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action – Best Ideas Virtual Investor Conference, which is being held virtually on May 16th – 20th, 2022.


Stacey Stevens, President and CEO of iCAD, Inc. will pre... Continue reading

Tags: Press Releases

iCAD Reports Financial Results for First Quarter Ended March 31, 2022

May 11, 2022
Category: Press Releases

Company to host conference call and webcast today at 4:30 PM ET

 

NASHUA, N.H. – May 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022.

 

Highlights:

Commercial reorganization shows early success leading to a ProFound AI® enterprise agreement at a world-renowned academic research... Continue reading
Tags: Press Releases

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology

April 28, 2022
Category: Press Releases

Leading healthcare provider with 14 imaging centers in North Carolina identified ProFound AI as the premier solution in a competitive trial based on unique workflow benefits and multivendor flexibility

 

 NASHUA, N.H. – April 28, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the next event in its “ProFound Insights, ProFound Impact” webinar series w... Continue reading

Tags: Press Releases

iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11

April 27, 2022
Category: Press Releases

NASHUA, N.H. – April 27, 2022 –  iCAD®, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.

 

Wednesday, May 11th at 4:30 PM ET

Domestic:                    888-506-0062

Continue reading

Tags: Press Releases

iCAD Announces Significant Commercial Momentum for ProFound AI® Among Customers Equipped with the Leading Provider of 3D Mammography Systems

April 26, 2022
Category: Press Releases

Customers report continued workflow advantages and clinical superiority with iCAD’s suite of AI‐powered breast health solutions, compared to other available breast AI solutions

 

 

NASHUA, N.H. – April 26, 2022 ‐ iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced significant commercial momentum for ProFound AI®, driving attachment to the leading provider of 3D... Continue reading

Tags: Press Releases

iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions

April 21, 2022
Category: Press Releases

Company expects preliminary estimated revenue to be .5 million

 

Timothy Norris Irish Appointed Chairman of the Board of Directors, Successor CFO search underway

 

NASHUA, N.H. – April 21, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader pro... Continue reading

Tags: Press Releases

iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27

April 19, 2022
Category: Press Releases

First event to feature Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio

 

NASHUA, N.H. – April 19, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will launch a new webinar series, ProFound Insights, ProFound Impact, which will highl... Continue reading

Tags: Press Releases

iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment

April 05, 2022
Category: Press Releases

Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers

 

 

NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that additional patients have been treated under the international multi-center GLIOX trial and customers globally are continui... Continue reading

Tags: Press Releases

Why ProFound AI Prevailed as the Premier AI Solution in a Competitive Trial at Wake Radiology

April 04, 2022
Category: iNFORMED - Blog

With 14 imaging locations in the Raleigh-Durham metropolitan area, also known as “the Triangle,” Wake Radiology offers a wide array of imaging exams in the outpatient setting, including both screening and diagnostic mammography. Renowned for state-of-the-art care, in August 2013 Wake Radiology began to upgrade to 3D mammography, or DBT, and now exclusively offers DBT at all 14 locations, all of which are designated as American College of Radiology Breast Imaging Centers of Excellence (BICOE).

 

“We pride o... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Density Breast Tomosynthesis Density Assessment Software Technology
wake-radiology-cary.jpg

Why Kettering Health Traded out Previous AI Software for ProFound AI® Enterprise-Wide

March 15, 2022
Category: iNFORMED - Blog

The Story of Kettering Health


A leading faith based, not-for-profit hospital system in southwest Ohio, Kettering Health has been providing quality patient care and cancer screening at its world-class cancer centers for 48 years. The team at Kettering takes great pride in ensuring that its facilities are equipped with the latest in state-of-the-art technology that empowers their team to provide the best possible patient care.

 

“... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Density Breast Tomosynthesis Density Assessment Software Technology
kettering-health-main.jpg

iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) Meeting

March 14, 2022
Category: Press Releases

World-leading breast cancer AI solutions featured for demonstration in iCAD booth


NASHUA, N.H., March 14, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI® for Digital Breast Tomosynthesis (DBT) in the iCAD booth (#4000) at the 2022 Healthcare Information and Management Sys... Continue reading

Tags: Press Releases

iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference

March 10, 2022
Category: Press Releases

iCAD’s award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership

 

NASHUA, N.H., March 10, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of innovative breast health solutions at the National Consortium of Breast Centers (NCoBC) Annual Confere... Continue reading

Tags: Press Releases

iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference

March 09, 2022
Category: Press Releases

NASHUA, N.H., March 9, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 32nd Annual Oppenheimer Healthcare Conference, taking place March 15-17, 2022.


Stacey Stevens, President and CEO of iCAD, Inc. is scheduled to present on Thursday, March 17, 2022, at 8:00 a.m. EST. The webcast of this event can be vi... Continue reading

Tags: Press Releases

iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite

March 02, 2022
Category: Press Releases

NVIDIA platform streamlines adoption, accelerates deployment of iCAD’s solutions in virtualized data centers

NASHUA, N.H. – March 2, 2022 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is among the first to validate its AI solutions with the NVIDIA® AI Ente... Continue reading

Tags: Press Releases

iCAD to Present at the 42nd Annual Cowen Health Care Conference

March 01, 2022
Category: Press Releases

NASHUA, N.H., March 1, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 42nd Annual Cowen Health Care Conference, taking place March 7-9, 2022.


Stacey Stevens, President and CEO of iCAD, Inc. is scheduled... Continue reading

Tags: Press Releases

iCAD Reports Financial Results For Fourth Quarter And Year Ended December 31, 2021

February 28, 2022
Category: Press Releases

Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation

 

Demonstrated compelling survival data for the use of Xoft® Brain IORT in recurrent glioblastoma (GBM) as published in Surgical Neurology International

 

Company to Host Conference Call & Webcast Today at 4:30 PM ET

 

Continue reading

Tags: Press Releases

iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28

February 14, 2022
Category: Press Releases

NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, February 28.


Monday, February 28th at 4:30 PM ET


Domestic:

877-407-0784

International:Continue reading

Tags: press releases

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon